Agios Pharmaceuticals, Inc. (AGIO) financial statements (2022 and earlier)

Company profile

Business Address 88 SIDNEY STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1,286671718805568574376
Cash and cash equivalents203127817110316172
Short-term investments817445484515321381245
Other undisclosed cash, cash equivalents, and short-term investments266981532201443259
Receivables (1)(1)(0) 58
Inventory, net of allowances, customer advances and progress billings 1571   
Inventory 1571   
Contract with customer, asset 219 
Other undisclosed current assets(222)(69)(122)(192)(123)(19)(47)
Total current assets:1,064637612614445560337
Noncurrent Assets
Finance lease, right-of-use asset011
Operating lease, right-of-use asset758594
Property, plant and equipment29323124242523
Long-term investments and receivables266981532201443259
Long-term investments266981532201443259
Other noncurrent assets31 0121
Total noncurrent assets:3742162792451695983
TOTAL ASSETS:1,438853891858614619420
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities49877560574931
Accounts payable17272218231715
Accrued liabilities32605342343216
Deferred revenue  11
Debt007    
Deferred revenue and credits1383922
Other undisclosed current liabilities117 33   
Total current liabilities:60949394958853
Noncurrent Liabilities
Long-term debt and lease obligation8698107    
Finance lease, liability001
Operating lease, liability8697106
Liabilities, other than long-term debt  511814417222
Deferred revenue and credits1814417222
Deferred revenue  51
Other undisclosed noncurrent liabilities(86)164 60   
Total noncurrent liabilities:863591577714417222
Total liabilities:14645325017123926175
Stockholders' equity
Stockholders' equity attributable to parent1,292400641688376359345
Common stock0000000
Treasury stock, value(802)      
Additional paid in capital2,3342,2432,1561,7941,175842630
Accumulated other comprehensive income (loss)(1)00(2)(1)(0)(0)
Accumulated deficit(239)(1,843)(1,516)(1,105)(798)(483)(285)
Total stockholders' equity:1,292400641688376359345
TOTAL LIABILITIES AND EQUITY:1,438853891858614619420

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues120311894437059
Revenue, net437059
Sublease income1  
Cost of revenue
(Cost of Goods and Services Sold)
 (3)(1)(1) (0)(0)
Gross profit:120011793437059
Operating expenses(378)(517)(543)(457)(364)(271)(178)
Other undisclosed operating income (loss)(1)  1 00
Operating loss:(378)(316)(426)(362)(321)(201)(119)
Nonoperating income1571516631
Investment income, nonoperating171516631
Other nonoperating income14      
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (18)    0
Loss from continuing operations before equity method investments, income taxes:(363)(327)(411)(346)(315)(198)(118)
Other undisclosed income (loss) from continuing operations before income taxes7     (0)
Net loss:(357)(327)(411)(346)(315)(198)(118)
Other undisclosed net income attributable to parent1,9610     
Net income (loss) available to common stockholders, diluted:1,605(327)(411)(346)(315)(198)(118)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(357)(327)(411)(346)(315)(198)(118)
Comprehensive loss:(357)(327)(411)(346)(315)(198)(118)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,960(0)2(1)(1)0(0)
Comprehensive income (loss), net of tax, attributable to parent:1,603(327)(409)(347)(316)(198)(118)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: